CBU
DYN icon

CIBC Bancorp USA’s Dyne Therapeutics DYN Stock Holding History

CIBC Bancorp USA’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$147K Buy
+11,641
New +$133K ﹤0.01% 1312

Other funds holding DYN

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

CIBC Bancorp USA's DYN Position: Q3 2025 in Review

CIBC Bancorp USA opened a new position in Dyne Therapeutics (DYN) in Q3 2025: 11,641 shares worth $147K. The stake represents ﹤0.01% of the portfolio and ranks #1312 among its holdings.

207 funds tracked by Wall St. Rank hold DYN as of Q3 2025.

  • CIBC Bancorp USA held 11,641 shares of Dyne Therapeutics worth $147K as of Q3 2025.
  • Dyne Therapeutics was a new CIBC Bancorp USA position in Q3 2025.
  • Dyne Therapeutics made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q3 2025, its #1312 holding.
  • 207 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q3 2025.

Based on CIBC Bancorp USA's 13F filing for Q3 2025, filed 12 Nov 2025.